Restoring invisible and abandoned trials – new podcast episode

Communications / 01 October 2020

Photo by Pau Casals on Unsplash

In the new episode of the Drug Safety Matters podcast, explore the problem of the data we don't see and find out what can be done to peel back the curtain.


Clinical trials are the “gold standard” of evidence-based medicine – the best way we have to test whether a drug is safe and effective before it enters the market. But if trial data is poorly reported or – even worse – left unpublished, how are we supposed to determine the true value of a medical treatment?

Peter Doshi, associate editor at The BMJ and founder of the Restoring Invisible and Abandoned Trials (RIAT) Support Center, has made it his mission to fix the problem and improve data transparency for good.

Subscribe by visiting the Drug Safety Matters website or listen in right here:

Learn more

To find out a lot more about Peter Doshi and his work, be sure to visit the RIAT Support Center here.

Peter Doshi on Drug Safety Matters. Photo: UMC

Peter Doshi on Drug Safety Matters. Photo: UMC

You may also like


Quick member survey – improving PV communication

If you have a spare couple of minutes, your input can help UMC continue to improve our pharmacovigilance communication methods.

Communications / 14 April 2022

Remembering Sten Olsson

A look back at Sten Olsson’s achievements with UMC and in pharmacovigilance internationally.

Communications / 01 June 2022

How to talk risk in a balanced way

Risks are not just numbers, but feelings. So how do you communicate risks accurately in a way that patients can interpret them? You give them facts, context, and trust.

Communications / 05 July 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more